Related Experiment Video
Updated: Aug 7, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
Neuroleptic malignant syndrome associated with metoclopramide
1Department of Psychiatry, University of Missouri, Columbia.
Abstract:
The case of neuroleptic malignant syndrome presented was associated with the use of metoclopramide, a dopamine-blocking agent, which is normally used in nonpsychiatric patients. The patient was successfully treated with dantrolene and bromocriptine. Nonpsychiatrist physicians should be aware of this complication of metoclopramide, as it is potentially fatal.
More Related Videos
09:33Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
08:57Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...